User:Rithish Nimmagadda: Difference between revisions
Jump to navigation
Jump to search
| (28 intermediate revisions by the same user not shown) | |||
| Line 20: | Line 20: | ||
==Pages Authored | ==Pages Authored== | ||
<div style="-moz-column-count:8; column-count: | <div style="-moz-column-count:8; column-count:2;"> | ||
#[[Epcoritamab-bysp]] | #[[Epcoritamab-bysp]] | ||
#[[Elfabrio]] | #[[Elfabrio]] | ||
#[[Mirikizumab-mrkz]] | #[[Mirikizumab-mrkz]] | ||
#[[Bimekizumab]] | |||
#[[Lotilaner]] | |||
#[[Quizartinib]] | |||
#[[Ritlecitinib]] | |||
#[[Tofersen]] | |||
#[[Retifanlimab-dlwr]] | |||
#[[Velmanase alfa-tycv]] | |||
#[[Elacestrant]] | |||
#[[Pirtobrutinib]] | |||
#[[vonoprazan, amoxicillin, and clarithromycin]] | |||
#[[Iptacopa]] | |||
#[[GERSTMANN-STRÄUSSLER-SCHEINKER SYNDROME]] | |||
#[[Rumination disorder]] | |||
#[[Birt-Hogg-Dubé syndrome]] | |||
#[[Ischemic hepatitis]] | |||
#[[Diffuse intrinsic pontine glioma]] | |||
#[[Myelin oligodendrocyte glycoprotein antibody-associated disease]] | |||
#[[Tolosa-Hunt syndrome]] | |||
==Pages Co-authored/Collaborated== | |||
#[[Eosinophilic esophagitis medical therapy]] | |||
#[[Migraine]] | |||
#[[Cardiac amyloidosis]] | |||
#[[Aspergillosis]] | |||
Latest revision as of 02:34, 10 August 2024
<nowiki>
Your Name
Rithish Nimmagadda,MBBS
Research scholar
Contact:945-278-1660
Email: rithishnvs@gmail.com [1]
Current Position
- research scholar (list chapters here)
Education
Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India
Pages Authored
- Epcoritamab-bysp
- Elfabrio
- Mirikizumab-mrkz
- Bimekizumab
- Lotilaner
- Quizartinib
- Ritlecitinib
- Tofersen
- Retifanlimab-dlwr
- Velmanase alfa-tycv
- Elacestrant
- Pirtobrutinib
- vonoprazan, amoxicillin, and clarithromycin
- Iptacopa
- GERSTMANN-STRÄUSSLER-SCHEINKER SYNDROME
- Rumination disorder
- Birt-Hogg-Dubé syndrome
- Ischemic hepatitis
- Diffuse intrinsic pontine glioma
- Myelin oligodendrocyte glycoprotein antibody-associated disease
- Tolosa-Hunt syndrome